Publication:
Effects of 18-month Vildagliptin Treatment on Portal Vein Pressure and Hepatosteatosis

Thumbnail Image

Organizational Units

Program

Authors

KARATOPRAK, CUMALİ
KISKAÇ, MUHARREM
Kilicarslan, Rukiye
ÇAKIRCA, MUSTAFA
Aydin, Sinem
Ozkan, Tuba

Advisor

Language

Publisher

Journal Title

Journal ISSN

Volume Title

Abstract

Objective: Patients with type 2 diabetes have an increased tendency to develop hepatosteatosis. The effects of drugs used to treat diabetes on the liver, regardless of the disease, are unknown.The aim of this study was to investigate the effects of vildagliptin, a dipeptidyl peptidase-4 inhibitor, on the portal vein pressure and hepatosteatosis in patients with type 2 diabetes in the 18 months of follow-up.

Description

Source:

Keywords:

Keywords

Citation

KARATOPRAK C., Kilicarslan R., ÇAKIRCA M., Aydin S., Ozkan T., ZORLU M., KISKAÇ M., -Effects of 18-month Vildagliptin Treatment on Portal Vein Pressure and Hepatosteatosis-, BEZMIALEM SCIENCE, cilt.7, ss.317-321, 2019

Endorsement

Review

Supplemented By

Referenced By

0

Views

2

Downloads

View PlumX Details


Sustainable Development Goals

Thumbnail Image
Goal